Stanford researchers have shown that blocking a single enzyme called 15-PGDH can regrow lost cartilage in aging mouse knees ...

Novel gedatolisib is currently under review at FDA for wild-type patients ...

A novel NLRP3 inhibitor reduced high-sensitivity C-reactive protein and other inflammatory biomarkers in patients at high ...

Weekly subcutaneous injections of the novel B-cell inhibitor obexelimab significantly reduces disease flares and lowers toxic ...

First-in-human trial of PS-1001 planned to initiate in 2027 - BOSTON and SINGAPORE, June 11, 2026 (GLOBE NEWSWIRE) -- Paratus Sciences (“Paratus”), a global biotechnology company decoding evolution to ...

Annual Meeting, 3H Pharmaceuticals released new clinical data for its wholly owned candidate, 3HP-2827. The ongoing study focuses on patients with advanced cholangiocarcinoma (CCA) and other solid ...

Kerry Rogers, MD, examines the underemphasized BTK inhibitor adverse effects that quietly erode patient quality of life—and ...

3D rendering of a checkpoint inhibitor binding PD-1, a protein on the surface of an immune T cell. This article is part of an ongoing series on checkpoint inhibitors, a novel cancer immunotherapy.

When researchers use an inhibitor to block a kinase’s activity, they generally expect to see less of the downstream effects of that kinase. So when neuroscientists observed the opposite using a new ...